Skip to main content

Seasonal Affective Disorder

2
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Extended-release bupropion hydrochloridePhase 3
Apollo Therapeutics
Apollo TherapeuticsUK - Cambridge
1 program
1
Light TherapyPhase 21 trial
Active Trials
NCT00269633Completed9Est. May 2008
Philips
PhilipsNetherlands - Amsterdam
1 program
goLITEN/A1 trial
Active Trials
NCT01462305Completed35Est. Apr 2012
GSK
GSKLONDON, United Kingdom
1 program
Extended-release bupropion hydrochloridePHASE_31 trial
Active Trials
NCT00046241Completed300Est. Jun 2003
Takeda
TakedaTOKYO, Japan
1 program
RamelteonPHASE_41 trial
Active Trials
NCT00502320Completed50Est. Jul 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaRamelteon
GSKExtended-release bupropion hydrochloride
Apollo TherapeuticsLight Therapy
PhilipsgoLITE

Clinical Trials (4)

Total enrollment: 394 patients across 4 trials

NCT00502320TakedaRamelteon

Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder

Start: Sep 2006Est. completion: Jul 200850 patients
Phase 4Completed
NCT00046241GSKExtended-release bupropion hydrochloride

Prevention of Seasonal Affective Disorder

Start: Sep 2002Est. completion: Jun 2003300 patients
Phase 3Completed
NCT00269633Apollo TherapeuticsLight Therapy

Research Study of Treatment for Winter Depression With Different Colors of Light

Start: Nov 2006Est. completion: May 20089 patients
Phase 2Completed
NCT01462305PhilipsgoLITE

30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder

Start: Jan 2012Est. completion: Apr 201235 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.